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Prescription of medicinal products constitutes one of the main 
activities of clinical practice with the primary purpose to assure the 
most advantageous treatment in case of particular disease. Due to 
rapid development of medical science and technologies, regulatory 
Authorities have continuously moved to implement new legislation 
and increase data required to grant a marketing authorization (MA) 
and assure quality, efficacy and safety of medicinal products.
However, approved medicines currently on the market do not 
address all public health therapeutic needs. Indeed, drugs for rare 
pathologies and dosage form suitable for a particular administration 
site or age-appropriate dosage forma doses formulated at different 
strength with safe excipients are not available. As matter of fact, MA 
of orphan drug is inhibited by the existence of often limited and weak 
clinical data at launch time. In the context of rare disease, it may 
prove difficult to recruit a sufficient number of patients and medical 
centers in clinical trials [1-3]. For many decades, also children were 
considered “therapeutic orphan” because of lack of clinical data and 
ethical concerns ruling out young patients; hence 67% of paediatric 
population received an unlicensed or off-label prescription.
When authorized medicines are not available or do not meet the 
specific needs of the patients, the physician can resort to prescribing 
compound medicines. Pharmacists are the only healthcare professionals 
formally trained in the art of compounding, thus the skills of the 
compounding pharmacists are needed to satisfy the individualized 
needs. Therefore, the pharmacist both in hospitals and community 
pharmacies has the duty to compound the extemporaneous medicine 
taking responsibility for ensuring that is of suitable quality, safe, stable 
and effective.
The European Pharmacopoeia contains a monograph about 
“Pharmaceutical preparations” which allows supplying unlicensed 
products extemporaneously prepared for a specific patient or made 
in larger batches for stock keeping. Despite the efforts made to assure 
the same level of quality and safety of industrial products, range of 
challenging issues remains. Indeed, safety and effectiveness of a drug 
product depends on the potency, purity and quality of ingredients, 
which in turn can be affected by the process of extemporaneous 
preparation. Risks in compounding are associated to errors of dose 
calculations or measurements, the use of incorrect formulae with no 
information of chemical, physical or microbiological stability, wrong 
method in compounding, incompatibility among ingredients and/or 
container and limited skills of pharmacists [4-6].
The regulation concerning the extemporaneous preparations in 
pharmacies falls under the national policies of each single State of the 
European Community and are not harmonised throughout Europe.
Over years, the competent Authorities have issued guides on 
pharmaceutical preparations with the intent to guarantee the safety 
and quality and to protect public health.
Following the structure from the Good Manufacturing Practices- 
Guide for industry, the PIC/S Guide was [7] lay out guidance on Good 
Practices (called Good Preparation Practice-GPP) on the preparation of 
medicinal products for human use only. This Guide examines how the 
potential risk for health damage in case of failure varies with different 
types of products and should therefore be assessed and documented by 
an appropriately competent person.
Examples are also provided to evidence how the potential risk could 
be mainly influenced by the probability of occurrence of a mistake, 
probability of detection of a possible mistake and, more important, the 
consequence on health of a possible mistake (health risk).
With a view to avoiding quality and safety gaps between 
extemporaneous and manufactured products, the Committee of 
Minister of the Council of Europe issued a resolution [8], recommended 
the introducing of two fundamental key concepts: the added value of all 
pharmacy preparations for humans and the risk assessment.
Medicinal products compounded in pharmacies, both 
extemporaneous and for stock are of added value whether they 
are needed by a specific patient or specific population groups with 
particular needs. Nevertheless, if a suitable pharmaceutical equivalent 
with a MA is available, the preparation should not be dispensed. 
Moreover, the professional involved in patient care should jointly 
undertake an appropriate assessment of the risk for the patient, which 
includes the risk posed by unlicensed medicinal product and the risk 
related to the unavailability of this medicinal product. 
The Resolution referred a risk-based decision matrix to 
individuate “high-risk preparations” and “low-risk-preparations”. The 
matrix is based on type of preparation; amount prepared annually, 
pharmacological effect of the active substances, preparation process 
and supply.
The Resolution recommended using the GMP Guide as a reference 
for an appropriate quality system for “high-risk preparations”, and 
the GPP Guide for “low-risk-preparations”. The application of other 
guidelines with an equivalent quality level is also accepted, depending 
on national legislation or guidance.
It is worthy to underline that this Resolution was the first 
at Community level, to introduce a simple criterion to classify 
preparations in two classes on the bases of the assessed risk and to 
guarantee the good level of quality.
Nevertheless, the current situation remains blurred since not all 
pharmacists are aware of these guides or evaluate the added value or 
apply the risk-based decision matrix to individuate the level of the 
quality system required for the pharmacy preparation process.
Finding a solution of these issues is one of the main challenges 
faced by the national authorities in the next years. Technical data, 
more frequently compounded formulations and a decision tree could 
be shared between scientific association and technical body (e.g. 
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Pharmacopeia Commission) in order to support professionals in the 
decision-making process, namely the prescriber and the pharmacist.
The competent authorities should also make an effort to harmonise 
rules in Europe aiming to protect the patient and public health and 
to guarantee the suitable standard of quality and safety of magistral 
preparations.
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